Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era

Abstract

Percutaneous coronary intervention with stenting is followed by a duration of dual antiplatelet therapy (DAPT) to reduce stent thrombosis and avoid target lesion failure. The period of DAPT recommended in international guidelines following drug-eluting stent implantation is 12 mo for most patients with acute coronary syndrome, and 6 mo for patients with chronic coronary syndrome or high bleeding risk. The new generation of drug-eluting stents have metallic platforms with thinner struts, associated with significantly less stent thrombosis. Shortened DAPT has been investigated with these stents, with evidence from randomised clinical trials for some individual stents showing non-inferior safety and efficacy outcomes. This has to be balanced by the effect of DAPT on secondary prevention of systemic cardiovascular disease especially in high-risk populations. This review will outline the current evidence for individual stents with regards to DAPT duration for both acute coronary syndrome and chronic coronary syndrome and discuss further directions for research and personalised medicine in this contemporary percutaneous coronary intervention era.

Key Words: Coronary artery disease; Drug-eluting stent; Percutaneous coronary intervention; Dual antiplatelet therapy; Stent thrombosis; Target lesion revascularization

Core Tip: The new generation of drug-eluting stents have different properties such as reduced strut thickness allowing lower level of local stent thrombosis, which may be feasible with shortened dual antiplatelet therapy (DAPT). Only a small number of individual stents have been validated for reduced DAPT, such as 1 mo for the BioFreedom stainless steel biolimus-eluting stent and the Onyx Resolute cobalt-chromium zotarolimus-eluting stent but in only certain populations. Future trials will compare DAPT durations within the same stent. Future research should also examine risk stratification and the parameters for patients to benefit the most from shortened DAPT.

INTRODUCTION

Percutaneous coronary intervention (PCI) is an interventional procedure which generally involves coronary angioplasty and stenting for individuals with coronary artery disease. Stent implantation is associated with greater lumen diameter increase in the acute period. The dimensions and the material of a stent are associated with different degrees of re-epithelialisation and risk of thrombosis. Intimal hyperplasia may cause restenosis of a vessel in bare metal stents (BMS), and metallic drug-eluting stents (DES) coated with anti-proliferative agents were developed to prevent this. However, delayed re-endothelialisation lengthens the duration of increased thrombosis risk. (Figure 1).

Figure 1 Percutaneous coronary intervention with stent implantation for coronary artery disease, and complications associated. PCI: Percutaneous coronary intervention; DAPT: Dual antiplatelet therapy.

Dual antiplatelet therapy (DAPT), which is a combination of aspirin and an oral inhibitor of the platelet P2Y12 inhibitor, is therefore recommended for a duration of time post stent implantation. Bare metal stents may only need 1 mo of DAPT, but the traditional duration for DAPT is at least 12 mo following drug-eluting stent insertion for low bleeding risk patients with acute coronary syndrome (ACS), which is Class I and Level I evidence in European Society of Cardiology and American College of Cardiology/American Heart Association Guidelines, and at least 6 mo for patients with stable coronary disease or with high bleeding risk[1,2]. High bleeding risk is defined as an increase of spontaneous bleeding during DAPT, which can be objectively calculated through risk scores such as PRECISE-DAPT[3,4].

However, the duration of this period has constantly been a subject of research, which has been influenced by the development of different P2Y12 inhibitors, and evolution of drug eluting stents with different materials and anti-proliferative agent. The newer generation of stents have reduced the risk of late and very late stent thrombosis. This yields the question of whether the full period for DAPT is required and/or could it be shortened. Shortening DAPT will reduce the risk of bleeding, reduce patient noncompliance, and will be more cost effective.

This clinical review will examine the current generation of stents, and evidence for the shortened length of DAPT post stent implantation for acute coronary syndrome and stable coronary disease in the contemporary PCI era.

NEW GENERATION DES

A DES comprises 3 main components: the metallic platform, the polymer, and the anti-proliferative agent (Table 1)[5-19].

Table 1 Current stents categorised by stent material, polymer, eluted drug, and shortened dual antiplatelet therapy duration validated for followed by aspirin or P2Y12 inhibitor monotherapy.

Stent	Metallic platform	Polymer	Anti-proliferative agent	DAPT duration validated for	Ref.
Onyx Resolute	Cobalt-chromium (has a platinum iridium core)	Permanent	Zotarolimus	1 mo	[5,6]
BioFreedom	Stainless steel	Polymer-free	Biolimus	1 mo1	[7,8]
Biomatrix; Biomatrix Flex	Cobalt-chromium	Bioresorbable	Biolimus	Standard/no short DAPT	[9,10]
Nobori	Cobalt-chromium	Bioresorbable	Biolimus	6 mo	[11]
Xience	Cobalt-chromium	Permanent	Everolimus	1-3 mo2	[12,13]
EluNIR	Cobalt-chromium	Permanent	Ridaforolimus	Standard/no short DAPT	[14]
Ultimaster; Orsino	Cobalt-chromium	Permanent	Sirolimus	Standard/no short DAPT	[15,16]
Cre8	Cobalt-chromium	Polymer-free	Amphilimus	Standard/no short DAPT	[17]
Xposition S (self-apposing)	Nickel-titanium	Permanent	Silolimus	Standard/no short DAPT	[18]
Promus	Platinium-chromium	Bioresorbable	Everolimus	6 mo	[12]
Synergy	Platinium-chromium	Bioresorbable	Everolimus	3 mo1	[19]

If there was no randomised control trial or prospective trial with a paired control investigating dual antiplatelet therapy (DAPT) duration, DAPT duration validated for is put down as ‘standard/no short DAPT.

¹All trials examined both acute coronary syndrome and chronic coronary syndromes, though the EVOLVE Short DAPT study and the One-Month DAPT trial did not include patients with myocardial infarction.

²The STOPDAPT-2 trial examined 1-mo DAPT followed by P2Y12 inhibitor therapy. DAPT: Dual antiplatelet therapy.

The metallic platform has a direct relationship with the dimensions of the stent. First-generation stents were constructed from stainless steel, but alloys such as cobalt-chromium, nickel-titanium, and platinum-chromium allow greater tensile strength with similar or reduced elasticity, allowing thinner struts[20]. Stainless steel stents normally have a strut of > 100 μm, but some of the newer second-generation stents such as the Orsino stent (60 μm), MiStent (64 μm), and BioMime (65 μm) are associated with 16% reduction in target lesion failure, and lower rates of any stent thrombosis in a meta-analysis of 10 trials[19]. Another meta-analysis of 69 trials comparing ultrathin (60-80 μm), thin (81-100 μm), intermediate (101-120 μm), and thick (≥ 120 μm) strut-thickness DES found that ultrathin devices had significantly less stent thrombosis (OR = 0.43, 95%CI: 0.27-0.68)[21].

Some stents have permanent or bioresorbable polymers which incorporate the anti-proliferative drug. Permanent polymers are non-biodegradable and allow continuous release of the drug. Bioresorbable polymers allow the effect of the drug to occur in the early phase of stent deployment and reverts to a bare metal stent once the polymer has become degraded, aiming to reduce very late stent thrombosis. The polymers used in first-generation stents were historically associated with delayed vascular healing and more very late stent thrombosis, but newer polymers are biocompatible. To avoid polymers entirely, some stents have the drug applied over the metallic platform of the DES in micropores. Many network meta-analyses have found no significant difference in stent thrombosis, target lesion revascularisation, very-late stent thrombosis (defined as ≥ 1 year after implantation), or clinical outcomes between the use of different polymers independent of struct thickness and metallic platform[22,23].

The anti-proliferative drugs tend to be immunosuppressive agents, and the majority comprise sirolimus, everolimus, biolimus, and zotarolimus. Other drugs also used include amphilimus and ridaforolimus. A meta-analysis showed no difference in stent thrombosis between zotarolimus and everolimus stent[24]. However, the cobalt-chromium sirolimus stent Orsino appeared to have less stent thrombosis than the stainless-steel biolimus stent Nobori, though this may have been due to other confounding factors such as metallic platform and strut thickness, which has been previously shown to affect thrombosis[25].

Bioresorbable vascular scaffolds (BVS) are an alternative option which fully resorbs over time. However, they are less favoured in PCI currently due to association with increased risk of stent thrombosis and target lesion failure during the first 3 years after implantation and would therefore be less suitable for consideration for shortened DAPT duration[26].

As reducing strut thickness appears to be associated with less stent thrombosis, the development of the current generation of ultrathin DES with smaller strut thickness raises the question of whether shortened DAPT may be suitable in these patients.

DECREASING DAPT DURATION

The success of a PCI, stent and DAPT regimen is measured by outcomes including target lesion failure, target lesion revascularisation, major adverse cardiovascular events including stroke, myocardial infarction (MI) and cardiac death, stent thrombosis, and bleeding events measured through Thrombolysis in Myocardial Infarction (TIMI) or Bleeding Academic Research Consortium (BARC).

SHORTENED DAPT WITH NEWER GENERATION DES

A systematic review and network meta-analysis analysed 17 randomised control trials comparing at least 2 of the 3 durations of DAPT (short term < 6 mo, standard term 12 mo, and long term > 12 mo) post PCI for both ACS and chronic coronary syndrome with DES deployment, and determined that there were higher rates of major bleeding (OR = 1.78, 95%CI: 1.27-2.49) and non-cardiac death (OR = 1.63, 95%CI: 1.03-2.59) in those on long-term treatment, and higher rates of any bleeding (OR = 1.39, 95%CI: 1.01-1,92), and no significant difference in other primary endpoints[27]. Additionally, assessing the subgroup of patients with newer-second generation DES found longer term DAPT had higher bleeding events and all-cause mortality compared to short-term DAPT (OR = 1.99, 95%CI: 1.04-3.81), but had similar efficacy and safety[27].

EVIDENCE FOR SHORTENED DAPT DURATION FOR SPECIFIC STENTS

Single-arm prospective studies with paired control

It appears that shortened DAPT may be suitable for some of the new second-generation DES. The STOPDAPT single-arm study was the first prospective study to examine DAPT shorter than 6 mo for the everolimus-eluting cobalt-chromium stent (CoCr-EES). The study enrolled 1525 patients to 3 mo of DAPT followed by aspirin monotherapy after the XIENCE CoCr-EES and compared this to the CoCr-EES group in the RESET trial as a historical control, where 90% had DAPT at 12 mo. At 1 year, the primary endpoint of cardiovascular death, myocardial infarction, stroke, stent thrombosis, and TIMI major/minor bleeding was less in the STOPDAPT than the RESET group (2.8% vs 4.0%, P = 0.06), and the incidence of stent thrombosis was lower in the STOPDAPT than in the RESET group (0% vs 0.3%, P = 0.03), suggesting that 3 mo was non-inferior to the historical control group[28].

The EVOLVE Short DAPT trial prospectively assessed the safety of 3-mo DAPT followed by aspirin monotherapy in high bleeding risk patients with the SYNERGY stent and compared this to a historical 12-mo DAPT control[19]. The primary results showed adjusted rate of death or MI in the following 3 to 15 mo was 5.6% in the 3-mo DAPT group, and 5.7% in the 12-mo control[19]. Unlike the other studies, this trial excluded acute myocardial infarction and complex lesions.

Randomised control trials

The STOPDAPT-2 randomised clinical trial examined patients undergoing PCI with the Xience CoCr-EES and randomised them to 1-mo DAPT followed by clopidogrel against 12 mo of DAPT for 3045 patients. 1-mo DAPT was superior to 12-mo DAPT (2.36% vs 3.70%, hazard ratio 0.64, P = 0.04 for superiority), for the primary endpoint, which was a composite of cardiovascular death, myocardial infarction, stroke, definite stent thrombosis, or TIMI major/minor bleeding at 12 mo[29]. There was slightly increased stent thrombosis for 1-mo DAPT compared to 12-mo DAPT (0.3% vs 0.07%, P = 0.21 for superiority), but this was not statistically significant. 1-mo DAPT was shown to be superior with statistical significance in secondary outcomes such as TIMI major/minor bleeding and BARC 3 or 5 bleeding at 1 year.

Further studies have examined reducing this time further and using aspirin as monotherapy. The two DES with most evidence for 1-mo DAPT are the BioFreedom DES and the Resolute Onyx DES.

The LEADERS FREE I double-blinded randomised control trial examined 2466 patients with a high risk of bleeding and randomised them to the BioFreedom Biolimus polymer-free stent or the Gazelle uncoated BMS with only one month of DAPT. The BioFreedom DES was shown to be superior for the primary safety endpoint of cardiac death, myocardial infarction, or stent thrombosis, and superior for the efficacy endpoint, defined as clinically driven target-lesion revascularization[7]. This was the first time 1-mo DAPT was shown to be feasible in a DES and favourably compared to a BMS, though limitations are that BMS only has a small indication possibly in patients who need urgent surgery in < 1 mo after stenting[30].

A randomised control trial of 3020 patients compared the BioFreedom DES with short 1-mo DAPT followed by aspirin monotherapy against other DES (BioMatrix and Ultimaster) with 6-12 mo DAPT was presented at the American Heart Association Scientific Sessions 2020[8]. They examined a composite primary outcome of cardiac death, nonfatal MI, target vessel revascularisation, cerebrovascular attack, or major bleeding. There was no difference in the BioFreedom short DAPT arm compared to the contemporary DES treatment arm (5.9% vs 6.5%, p for noninferiority < 0.001, P for superiority 0.475). There was no statistical difference in the individual components of the composite. This included patients with and without a high bleeding risk, but did not include patients with myocardial infarction. However, an intention-to-treat analysis was used for this study, and 17% of patient remained on DAPT at 1.5 mo. Additionally, the DES that BioFreedom was compared to had not been given FDA approval for use, so the comparison group was not the current best available therapy.

The ONYX ONE Global trial randomised 1996 patients to the BioFreedom DES and the Resolute zotarolimus-eluting Onyx DES, both with 1-mo DAPT followed by single antiplatelet therapy with aspirin or P2Y12 inhibitor. Inclusion criteria were those with high bleeding risk (adjunctive oral anticoagulation to continue after PCI, age ≥ 75, baseline haemoglobin < 110 g/L, previous intracerebral bleed, stroke in the last 12 mo, hospital admission for bleeding during the last 12 mo, nonskin cancer diagnosed or treated ≤ 3 years, planned daily NSAID or steroids for ≥ 30 d after PCI, planned surgery that would require interruption of DAPT within the next 12 mo, renal failure CrCl < 40 mL/min, thrombocytopenia < 100000/mm³, severe chronic liver disease, expected noncompliance to prolonged DAPT). 51% of these had acute coronary syndrome, and 32% had atrial fibrillation. They found no significant difference between Resolute and BioFreedom in primary outcomes of composite cardiac death/myocardial infarction/stent thrombosis (17.1% vs 16.9% P = 0.011 noninferiority, P = 0.84 superiority). The myocardial infarction rate was very high in both Resolute and BioFreedom (13.4% vs 14.7%), which may represent the high-risk population, but the lack of a comparison with a 3 to 6-mo DAPT regimen means this cannot be completely separated from the use of 1-mo DAPT. Additionally, BARC 2-5 bleeding was high in both groups, reflecting the high bleeding risk inclusion criteria, being slightly higher in the Resolute group but not statistically significant (15.1% vs 13.7%, P = 0.4)[5]. The Onyx One Clear Study complemented this by examining 1506 patients who had DAPT adherence and without major adverse events during the first month and found the primary endpoint of cardiac death or myocardial infarction at 1 year at be 7.0%. The Resolute Onyx DES therefore became the first 1-mo DAPT indication for high bleeding risk patients in Europe, and was FDA approved for use in the United States[6].

Observational studies

There appear to be some observational studies with evidence for shortened DAPT. The Ultimaster stent had similar rates of a composite measure of target lesion vascularisation, cardiac death, and MI for 6-mo and 12-mo DAPT in an observational study[15]. Similarly, for the Cre8 stent, an observational study showed no significant difference between patients discharged with ≤ 3-mo DAPT due to high bleeding risk or urgent non-cardiac surgery and regular DAPT duration ≥ 6 mo for a composite endpoint of target vessel revascularisation, cardiac death, and MI[17]. Although this does show the real-world feasibility of shortened DAPT for this population of patients, the lack of a randomised control means that there is limited information for the direct comparison of DAPT duration.

Planned studies and future directions

EXCELLENT was a randomised control trial examining 6-mo DAPT compared to standard 12-mo DAPT in 1443 patients with the XIENCE/Promus everolimus stent which demonstrated non-inferiority for target vessel failure[11]. However, stent thrombosis appeared to occur more, and the study appeared underpowered for death and myocardial infarction. The XIENCE Short DAPT Program was announced in 2020, consisting of a series of 3 single-arm trials investigating 3-mo and 1-mo duration in patients undergoing PCI with XIENCE compared with historical controls[12].

Similarly, the prospective multicentre REIWA registry was announced in 2020 to investigate very short DAPT for patients with biodegradable polymer DES, such as the Synergy, Ultimaster, or Orsino. It will investigate the safety and feasibility of 1-mo DAPT followed by P2Y12 inhibitor monotherapy, much like the STOPDAPT-2 trial, but this time on bioresorbable-polymer DES rather than permanent-polymer DES[31].

Further focus could examine the use of P2Y12 inhibitor monotherapy for these stents, as this has been proved useful in the STOPDAPT-2 randomised clinical trial, or trials focusing on purely aspirin, unlike the ONYX ONE global trial. As well as clopidogrel monotherapy, ticagrelor monotherapy has also been investigated, where high-risk patients with PCI and 3-mo of DAPT continued with ticagrelor and were randomised to aspirin or placebo for one year. This showed death from any cause, MI, or stroke was 3.9% in both groups, but the 3-mo group had a lower incidence of clinically significant bleeding, warrant this as an area for further research[32]. A direct comparison of DAPT lengths between groups of 1-mo vs 3-mo and 6-mo DAPT can be carried out and keeping the stent type constant. Very short DAPT can be assessed in specific non-high bleeding risk patient groups to broaden the population validated for (Table 2).

Table 2 Summary of evidence of shortened dual antiplatelet therapy duration for specific stents from randomised control trials and single-arm prospective studies with a historical control.

	Population	Study	Intervention	Control	Primary endpoint
Single-arm study	ACS (32%) and CCS (68%)	STOPDAPT[28]	1525 patients, XIENCE CoCr-EES with 3-mo DAPT followed by aspirin monotherapy	1559 patients, Endeavor CoCr-EES approximately 90% with 1-yr DAPT followed by aspirin monotherapy (RESET trial)	12-mo cardiovascular death, MI, stroke, thrombosis, bleeding; 2.8% vs 4.0% (P = 0.06)
	No acute myocardial infarction, High bleeding risk	EVOLVE Short DAPT[19]	1487 patients, SYNERGY stent with 3-mo DAPT followed by aspirin monotherapy	1493 patients, 1-year DAPT	3-15 mo death or MI; 5.6% vs 5.7% (P = 0.0016 non-inferiority)
RCT	ACS (38%) and CCS (62%)	STOPDAPT-2[29]	1523 patients, XIENCE CoCr-EES with 1-mo DAPT followed by clopidogrel monotherapy	1522 patients, XIENCE CoCr-EES with 12-mo DAPT	12-mo Cardiovascular death, MI, stroke, thrombosis, bleeding; 2.36% vs 3.70% (superiority P = 0.04)
	ACS (42%) and CCS (58%); High bleeding risk	LEADERS FREE I[7]	1196 patients, BioFreedom DES with 1-month DAPT followed by one antiplatelet	1189 patients, Gazelle uncoated BMS with 1-month DAPT followed by one antiplatelet	390 d cardiovascular death, MI, stent thrombosis 9.4% vs 12.9% (P = 0.005 superiority)
	No acute myocardial infarction	One-month DAPT trial[8]	1507 patients, BioFreedom DES with 1-mo DAPT followed by aspirin monotherapy	1513 patients, BioMatrix and Ultimaster DES with 6-12 mo DAPT	12-mo cardiovascular death, MI, target vessel revasculariation, stroke, major bleeding; 5.9% vs 6.5% (noninferority P < 0.001)
	ACS (62%) and CCS (38%)High bleeding risk	ONXY ONE Global[5]	1003 patients, Resolute Onyx DES with 1-mo DAPT followed by one antiplatelet	993 patients, BioFreedom DES with 1-mo DAPT followed by one antiplatelet	Cardiac death, MI, thrombosis 17.1% vs 16.9% (P = 0.011 noninferiority)

ACS: Acute coronary syndrome; DAPT: Dual antiplatelet therapy; CoCr-EES: Everolimus-eluting cobalt-chromium stent; DES: Drug-eluting stents; MI: Myocardial infarction.

DAPT DURATION DETERMINED BY SECONDARY PREVENTION OF SYSTEMIC CARDIOVASCULAR DISEASE

Although the characteristics of the newer generation of stents may be associated with the feasibility of shortened DAPT to reduce local stent thrombosis, it may be balanced out by the effect of DAPT on secondary prevention of systemic thrombosis and major adverse cardiovascular events. The PEGASUS-TIMI 54 randomised control trial examined patients ≥ 50 years old with at least one additional high-risk feature and spontaneous MI 1-3 years before enrolment. These included ≥ 65 years, diabetes mellitus, second myocardial infarction, multivessel disease, or chronic renal dysfunction. 60mg ticagrelor twice a day had marginally higher absolute benefit in terms of the primary efficacy endpoint than the absolute harm in the primary safety endpoint[33]. The DAPT trial compared 12 mo of DAPT with 30 mo of DAPT and showed an absolute risk reduction in the primary efficacy end point of the composite of death, MI, and stroke by 1.6%, and stent thrombosis by 1%[34].

A meta-analysis which included PEGASUS along with other studies with clopidogrel and prasugrel found prolonged DAPT decreased major adverse cardiac events and cardiovascular deaths compared with aspirin, but it was associated with a significant risk of bleeding, and no difference in all-cause mortality[35]. However, the efficacy may have been underestimated by PEGASUS, which allowed patients who had been off DAPT for several years to restart therapy. European and American guidelines therefore recommend consideration of prolonged DAPT in patients at low risk of bleeding with class IIb evidence[1-3].

PERSONALIZED ASSESSMENT OF DAPT DURATION

With the development of risk stratification and personalised medicine, DAPT duration will also be influenced by patient factors. The PRECISE-DAPT score is used at the time of stenting to determine whether the patient may benefit from 3-6 mo short DAPT or 12-24 mo standard/DAPT, and the DAPT score is used after 12 mo of DAPT to determine whether DAPT can be stopped, or if the patient should continue it to 30 mo. The PRECISE-DAPT score uses factors such as Hb, WBC, age, creatinine clearance, and prior bleeding[4]. The DAPT score uses patient factors such as age, smoking, diabetes mellitus, previous stenting or myocardial infarction, but also disease factors such as stent characteristics (diameter, paclitaxel, vein graft stent), left ventricular ejection faction, myocardial infarction at presentation[36]. A further risk scoring model was generated from the Patterns of Non-Adherence to Anti-Platelet Regimen in Stented Patients (PARIS) registry, which calculates a risk score for both ischaemia and major bleeding at 24 mo post PCI to inform decision-making[37]. The coronary thrombotic events score used the factors of diabetes mellitus, ACS, smoking, renal function, previous PCI, and previous CABG. The bleeding events score used the factors of age, body mass index, smoking, anaemia, renal function, and triple therapy on discharge[37]. However, these have not been prospectively validated in a randomised control trial. The approval of the Onyx DES indicated for high bleeding risk patients is a step towards the personalised assessment of DAPT duration, and future research will focus on further parameters and patient stratification to identify individuals which may benefit from very short DAPT.

CONCLUSION

The period of DAPT following PCI is an area of research which has been increasingly focused on with the current cohort of contemporary DES. New stents such as the Orsino, MiStent, and BioMime are associated with thinner struts which are generally associated with less late thrombosis and may be suitable for shortened DAPT. This has been supported by a network meta-analysis which demonstrated less all-cause mortality for shortened DAPT duration (3-6 mo) compared to standard DAPT duration in the subgroup of patients with newer second-generation DES.

The STOPDAPT and STOPDAPT-2 trials directly examined the feasibility of shortened DAPT duration of less than 6 mo with CoCr-EES. STOPDAPT showed no significant difference in primary outcomes of bleeding, stent thrombosis, cardiovascular death or myocardial infarction between 3-mo DAPT followed by aspirin monotherapy against 6-12 mo DAPT, and STOPDAPT-2 showed superiority of 1-mo DAPT followed by clopidogrel monotherapy against 6-12 mo DAPT for the same composite outcome but including stroke. These are two studies which have allowed a direct comparison of DAPT timings within the same type of DES.

Some patients may benefit from shortened DAPT more due to their high bleeding risk or need to be on monotherapy by a certain point. These are patients who may have coagulation abnormalities, previous significant bleeding, recent malignancy, severe kidney or liver dysfunction, or are due to undergo timely surgical procedures. Assessing this patient subgroup for shortened DAPT trials may show greater benefit in terms of composite outcome of stent thrombosis, bleeding, cardiovascular death or myocardial infarction. The Resolute Onyx DES was tested in this population and has subsequently received a 1-mo DAPT indication in Europe and the United States. The BioFreedom DES was tested in patients both with and without a high bleeding risk. However, the limitation of these trials was the comparison against DES which were not currently licensed or standard management. Future research should focus on comparison against contemporary DES representative of current therapy, and direct comparison of DAPT duration for the same stent. There are currently registries and trials undergoing for the XIENCE, Synergy, Orsino, and Ultimaster stent, allowing direct comparison of DAPT duration in the same stent.

In addition to local effects to prevent stent thrombosis, recent evidence suggests that DAPT is useful for secondary prevention of systemic thrombosis and preventing future major adverse cardiovascular events, especially in patients with high-risk features such as diabetes mellitus, a second myocardial infarction, or multivessel disease. European Society of Cardiology and American College of Cardiology/ American Heart Association guidelines support the consideration of extended DAPT for these patients.

Therefore, we are gradually moving from a “one size fits all approach” towards an era of personalised medicine where different parameters are identified to guide DAPT duration, which is reflected in current international guidelines. The development of risk scores to guide DAPT duration reflects this shift, but these remain to be clinically validated.

The contemporary PCI era brings a new generation of stents which may be beneficial, some of which are validated for shortened DAPT especially in patients with high bleeding risk. Further research is required to assess which other patient groups may benefit from this shortened DAPT approach, and balance this against the patient groups which may benefit from systemic antiplatelet therapy.